18F-FDG PET/CT for Response Assessment in Lung Cancer

Elsevier

Available online 29 May 2022

Seminars in Nuclear Medicine

Treatment response assessment in lung cancer is crucial in the management strategy and outcome of patients. Accurate treatment response assessment can guide the treating physicians and improve patient survival. Anatomic and metabolic tumor response assessments have been evaluated extensively, showing a positive impact in the management of these patients. 18F-FDG PET/CT provides early and more specific treatment response assessments, preceding anatomic changes in these tumors. Familiarity with the different treatment response assessment algorithms, criteria, time intervals, imaging pitfalls is essential for treating physicians and nuclear radiologists to provide accurate response assessments. Artificial Intelligence is being more frequently explored for this purpose and can assist physicians in providing prompt and accurate treatment response assessments.

View full text

© 2022 Published by Elsevier Inc.

留言 (0)

沒有登入
gif